Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s What Happened

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped up before the market opened on Friday . The stock had previously closed at $25.40, but opened at $26.74. Capricor Therapeutics shares last traded at $26.6190, with a volume of 2,666,751 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday. HC Wainwright upped their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Finally, Roth Capital raised their target price on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.30.

Capricor Therapeutics Trading Up 7.4%

The company has a market cap of $1.25 billion, a P/E ratio of -15.07 and a beta of 0.61. The business has a 50 day moving average price of $7.19 and a 200-day moving average price of $8.14.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). On average, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Octagon Capital Advisors LP acquired a new position in Capricor Therapeutics during the first quarter worth approximately $4,270,000. GSA Capital Partners LLP bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $1,555,000. Two Sigma Investments LP increased its holdings in shares of Capricor Therapeutics by 128.3% during the 3rd quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock worth $2,565,000 after acquiring an additional 199,959 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Capricor Therapeutics by 1,629.9% during the 3rd quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock worth $1,379,000 after acquiring an additional 180,234 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Capricor Therapeutics in the 1st quarter valued at $1,547,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.